Why the study?
Genetic loss-of-function variants in ANGPTL3 are associated with lower levels of plasma lipids, leading to the development of vupanorsen, an antisense oligonucleotide inhibiting ANGPTL3 protein synthesis.
Does vupanorsen reduce non-HDL-C in statin-treated adults with elevated cholesterol and triglycerides?
Comparison
1 of 7 vupanorsen dose regimens vs placebo
Design
Double-blind randomized controlled trial
Follow-up
24 weeks
Loading...
Supports ANGPTL3 inhibition as statin add-on for dyslipidemia; extends genetic loss-of-function data to pharmacological target validation.
Does vupanorsen reduce non-HDL-C in statin-treated adults with elevated cholesterol and triglycerides?
Vupanorsen significantly reduces non-HDL-C and triglycerides in statin-treated patients but is associated with dose-dependent increases in liver enzymes and hepatic fat fraction.
A 2022 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: